Systematic Analysis of Chemokines Reveals CCL18 is a Prognostic Biomarker in Glioblastoma
Wenqing Gao,Yuanyuan Li,Teng Zhang,Jianglong Lu,Jiasong Pan,Qi Qi,Siqi Dong,Xiangjun Chen,Zhipeng Su,Jixi Li
DOI: https://doi.org/10.2147/JIR.S357787
IF: 4.5
2022-04-28
Journal of Inflammation Research
Abstract:Wenqing Gao, 1, &ast Yuanyuan Li, 1, &ast Teng Zhang, 1 Jianglong Lu, 2 Jiasong Pan, 1 Qi Qi, 1 Siqi Dong, 3 Xiangjun Chen, 3, 4 Zhipeng Su, 2 Jixi Li 1, 4 1 State Key Laboratory of Genetic Engineering, Department of Neurology, Huashan Hospital and Institute of Neurology, School of Life Sciences, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Shanghai, 200438, People's Republic of China; 2 Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China; 3 Department of Neurology, Huashan Hospital and Institute of Neurology, Fudan University, Shanghai, 200040, People's Republic of China; 4 National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhipeng Su; Jixi Li, Email ; Background: Glioblastoma (GBM) is the most common and aggressive brain tumor in adults, in which chemokines are often upregulated and may play pivotal roles in their development and progression. Chemokines are a large subfamily of cytokines with leukocyte chemotactic activities involved in various tumor progression. However, gene expression patterns of the chemokines on a global scale were not known in GBM. Methods: Differentially expressed chemokine genes in glioma and normal samples were screened by using The Cancer Genome Atlas (TCGA) database. Cox regression identified the prognosis-related genes in each glioma subtype. The protein expression levels of chemokines in 72 glioma tissues were detected by ELISA. Results: We found that the transcripts of seven chemokines, including CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13, were highly expressed in GBM that evidenced by involving immune cell infiltration regulation and accompanied with worse outcomes of GBM patients. The prognostic nomogram construction demonstrated that CCL18 held the highest risk score in patients with GBM. Furthermore, experiments on 72 glioma tissue samples confirmed that CCL18 protein expression was positively associated with tumor grade and IDH1 status but inversely with glioma patients' overall survival (OS). Conclusion: Our study reveals comprehensive and comparable roles of chemokine members in glioblastoma, and identified CCL18 as a critical driver of GBM malignant behaviors, therefore providing a potential target for developing prognosis and therapy in human glioblastoma. Keywords: chemokines, GBM, biomarker, overall survival, prognosis Glioblastoma (GBM) is the most common primary malignant tumor in the brain, with an incidence rate of approximately 3.47 per 100,000 people. 1 GBM, the World Health Organization (WHO) grade IV glioma, has the worst prognosis. 2 Though there are varieties of approved treatments for GBM, including surgical resection, radiotherapy, and chemotherapy, the clinical outcome remains dismal. 3 For primary GBM patients, the median overall survival (OS) time was eight months with 95% confidence intervals, and the five‐year survival rate was only about 6.8%. 1 The possible reasons are the highly invasive nature of GBM cells, the chemo‐ and radio‐resistance, the high level of vascularization, complex cell composition, and decreased effusion of chemotherapeutic drugs due to the blood-brain barrier (BBB). 4,5 Many prognosis biomarkers for GBMs have been developed, such as mutations in isocitrate dehydrogenase (IDH) genes, MGMT gene promoter methylation status, chromosome 1p/19q deletion, and tumor protein P53 mutation. 1,2 In the WHO 2016 classification, secondary glioblastomas with an IDH mutation originate from lower grade precursor lesions. 2 Significantly, mutations in IDH1 are correlated with a better prognosis. However, these mutations are rarer in primary GBM than in most common adult gliomas. 6 Moreover, antiangiogenic treatments like anti-VEGFR/VEGF drugs do not have significant improvement in survival. Monoclonal antibody bevacizumab might improve life quality, but not OS or progression-free survival (PFS) of GBM patients. 7 Consequently, further efforts are urgently needed to understand the biological behavior of GBM and develop novel methods for diagnosis and treatments. The tumor microenvironment (TME), one of the critical factors of GBM development and treatment, is the primary interaction location between tumor cells and the host immune system. 8 Through interactions between chemokines and chemokine recepto -Abstract Truncated-
immunology